Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Blog Article
Objectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic squamous non-small cell click here lung cancer (sq-NSCLC).However, the cost-effectiveness of this treatment in China remains to be determined.In this study, we aimed to assess the cost-effectiveness of penpulimab combined with paclitaxel and carboplatin for metastatic sq-NSCLC.Design Based on the AK105-302 trial (NCT03866993), a Markov model was created to evaluate the disease progression of metastatic sq-NSCLC patients over 10 years.
The model included progression-free survival, progressive disease and death.The utility values were derived from published literature.Sensitivity studies were used to assess the robustness of the model outputs.Setting The Chinese healthcare system perspective.
Participants A hypothetical Chinese cohort of patients with locally animed blue lotion topical spray advanced or metastatic sq-NSCLC.Interventions Penpulimab plus chemotherapy versus chemotherapy.Primary outcome measure Costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER).Results Compared with the chemotherapy alone group, the cost of penpulimab plus chemotherapy increased by US$3717.
72, with an increase of 0.43 QALYs.The ICER was US$8625.78/QALY, which was well below the willingness-to-pay threshold of US$38 052/QALY.
This demonstrated higher cost-effectiveness benefits, as confirmed by the sensitivity analysis results.Conclusions Under the Chinese health system, penpulimab plus paclitaxel and carboplatin is cost-effective for metastatic sq-NSCLC patients and can be used as an economical and effective treatment option.